Mustang Bio, Inc. (MBIO)
Nasdaq: MBIO · Pharmaceutical Preparations · Waltham, MA · filing with the SEC since 2016
Who owns Mustang Bio, Inc.
As filed with the SECHolders of 5% or more
1
Fortress Biotech, Inc. holds 8% of Common Stock, $0.0001 Par Value, as its SCHEDULE 13D/A filed Jan 5, 2026 says.
Directors and officers
4
report now, of 12 people on the record since 2016. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Fortress Biotech, Inc.
SCHEDULE 13D/A · filed Jan 5, 2026 · Common Stock, $0.0001 Par Value · 4% in Oct 1, 2025
Mitchell P. Kopin
SCHEDULE 13G/A · filed Aug 12, 2025 · Common stock, par value $0.0001 per share · reported falling below 5%, from 8.8% in May 9, 2025
Armistice Capital, LLC
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 9.99% in Feb 14, 2025
What MBIO reports owning in othersstakes of 5% or more, and other ties
Mustang Bio, Inc. reports no stake in another company in the record.
Insider tradesForm 4
2sales
1purchases
0sales on a scheduled plan
2people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2025 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window3 of 13 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Jin David | director | 0 | $0 | 0 | 1 | $0 |
| Chill Adam J. | director | 1 | $0 | 0 | 0 | $0 |
| Herskowitz Neil | director | 1 | $0 | 0 | 0 | $0 |